SCHEMBL6800432

SCHEMBL6800432

Cc1ccc(-c2ccccc2C(=O)Nc2ccc(NCCc3cccc(N)n3)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.46
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
OPRL1 P41146 1/20 0.45
KMT2A Q03164 1/20 0.44
CHRNB2 P17787 1/20 0.44
CHRNB4 P30926 1/20 0.44
CHRNA3 P32297 1/20 0.44
CHRNA4 P43681 1/20 0.44
KDR P35968 2/20 0.44
POLB P06746 1/20 0.43
GAA P10253 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 2/20 0.43
TP53 P04637 2/20 0.43
HTT P42858 2/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6501885 0.91 GCGR (0.44) L3MBTL1NPC1RAB9AOPRL1KMT2A
SCHEMBL6492232 0.91 CYP3A4 (0.41) L3MBTL1NPC1RAB9AOPRL1KMT2A
SCHEMBL6798535 0.91 ATR (0.44) L3MBTL1NPC1RAB9AOPRL1CHRNB2
SCHEMBL6792277 0.90 NPC1 (0.46) L3MBTL1NPC1RAB9AOPRL1KMT2A
SCHEMBL6788782 0.89 GAA (0.59) NPC1RAB9AKMT2APOLBGAA
SCHEMBL6489781 0.88 L3MBTL1 (0.47) L3MBTL1OPRL1KMT2ACHRNB2CHRNB4
SCHEMBL6791861 0.88 PTGS1 (0.51) KDRALDH1A1SMN1; SMN2KIT
SCHEMBL6499114 0.88 HDAC7 (0.47) L3MBTL1OPRL1KMT2ACHRNB2CHRNB4
SCHEMBL6793279 0.86 POLB (0.47) L3MBTL1NPC1RAB9AOPRL1KMT2A
SCHEMBL6487481 0.86 F10 (0.43) L3MBTL1NPC1RAB9AKMT2AKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US claimed
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed
EP-1326835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-07-16 EP disclosed
WO-2002028835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 L3MBTL1 1793/4885NPC1 64/4885RAB9A 3707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.